Skip to main content

Table 1 Effect of the tested drugs on BGL in alloxan-induced diabetic rats

From: Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes

BGL mg/dL
Groups Week 1 Week 2 Week 3 Week 4
Normal control group 136.5 ± 18.52 121.33 ± 12.08 119.25 ± 11.35 109 ± 10.92
Diabetic control group 359.75 ± 45.13* 328 ± 141.34* 428.5 ± 121.17* 396.5 ± 80.60*
Diabetic group treated with bromocriptine 191 ± 16.89# 199.25 ± 65.05# 238.25 ± 56.88# 284.25 ± 148.00#
Diabetic group treated with Cabergoline 213.75 ± 37.74# 211.75 ± 38.62# 293 ± 213.15# 280.25 ± 220.48#
Diabetic group treated with sarpogrelate 326.25 ± 93.45 298.25 ± 122.37 393.75 ± 118.77 369.75 ± 43.15
Diabetic group treated with bromocriptine + sarpogrelate 247.75 ± 50.35# 215.5 ± 33.20# 310.25 ± 70.59# 288.25 ± 109.41#
Diabetic group treated with cabergoline + sarpogrelate 196 ± 54.20# 158.75 ± 35.01# 235.5 ± 182.22# 215.75 ± 141.46#
  1. Values shown are means ± SEM; n = 6 rats per group. * P < 0.05, significantly different from the normal control group; # P < 0.05, significantly different from the diabetic control group